Generate Biomedicines, Inc. (GENB)
NASDAQ: GENB · Real-Time Price · USD
12.44
-0.01 (-0.12%)
Apr 28, 2026, 4:00 PM EDT - Market closed
Generate Biomedicines Stock Forecast
Stock Price Forecast
The 5 analysts with 12-month price forecasts for Generate Biomedicines stock have an average target of 23.2, with a low estimate of 16 and a high estimate of 30. The average target predicts an increase of 86.57% from the current stock price of 12.44.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Generate Biomedicines stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Apr '26 |
|---|---|
| Strong Buy | 3 |
| Buy | 3 |
| Hold | 0 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Initiates $16 | Strong Buy | Initiates | $16 | +28.67% | Apr 13, 2026 |
| Goldman Sachs | Goldman Sachs | Strong Buy Initiates $26 | Strong Buy | Initiates | $26 | +109.09% | Mar 24, 2026 |
| Morgan Stanley | Morgan Stanley | Buy Initiates $20 | Buy | Initiates | $20 | +60.84% | Mar 24, 2026 |
| Piper Sandler | Piper Sandler | Buy Initiates $24 | Buy | Initiates | $24 | +93.00% | Mar 24, 2026 |
| Cantor Fitzgerald | Cantor Fitzgerald | Buy Initiates n/a | Buy | Initiates | n/a | n/a | Mar 24, 2026 |
Financial Forecast
Revenue This Year
30.28M
from 31.89M
Decreased by -5.05%
Revenue Next Year
35.30M
from 30.28M
Increased by 16.58%
EPS This Year
-2.22
from -4.98
EPS Next Year
-2.22
from -2.22
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 42.0M | 42.0M | |
| Avg | 30.3M | 35.3M | |
| Low | 19.6M | 23.4M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | 31.7% | 38.7% | |
| Avg | -5.1% | 16.6% | |
| Low | -38.5% | -22.9% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | -2.11 | -2.14 | |
| Avg | -2.22 | -2.22 | |
| Low | -2.29 | -2.27 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 |
|---|---|---|---|
| High | - | - | |
| Avg | - | - | |
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.